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OBJECTIVES We report the largest and the longest follow-up to date of patients who underwent
transcatheter patent foramen ovale (PFO) closure for paradoxical embolism.
BACKGROUND Closure of a PFO has been proposed as an alternative to anticoagulation in patients with
presumed paradoxical emboli.
METHODS Data were collected for patients following PFO closure with the Clamshell, CardioSEAL or
Buttoned Devices at two institutions.
RESULTS There were 63 patients (46 6 18 years) with a follow-up of 2.6 6 2.4 years. Fifty-four (86%)
had effective closure of the foramen ovale (trivial or no residual shunt by echocardiography)
while seven (11%) had mild and two (3%) had moderate residual shunting. There were four
deaths (leukemia, pulmonary embolism, sepsis following a hip fracture and lung cancer).
There were four recurrent embolic neurological events following device placement: one stroke
and three transient events. The stroke occurred in a 56-year-old patient six months following
device placement. A follow-up transesophageal echocardiogram showed a well seated device
without residual shunting. Two of the four events were associated with suboptimal device
performance (one patient had a significant residual shunt and a second patient had a “friction
lesion” in the left atrial wall associated with a displaced fractured device arm). The risk of
recurrent stroke or transient neurological event following device placement was 3.2% per year
for all patients.
CONCLUSION Transcatheter closure of PFO is an alternative therapy for paradoxical emboli in selected
patients. Improved device performance may reduce the risk of recurrent neurological events.
Further studies are needed to identify patients most likely to benefit from this intervention.
(J Am Coll Cardiol 2000;35:1311–6) © 2000 by the American College of Cardiology
The association of patent foramen ovale (PFO) and cere-
brovascular events in selected patients is becoming increas-
ingly established (1–7), with the underlying mechanism
thought to be passage of emboli through the foramen
(8–12). This association appears to be particularly strong in
young patients with stroke (3,13). To our knowledge, the
most appropriate therapy to prevent future embolic cerebro-
vascular events in patients with PFO has not been estab-
lished (14–16). Anticoagulation and surgical closure have
been proposed as measures to prevent recurrent neurological
events (8,15–18). However, both surgical closure and long-
term anticoagulation therapy have significant associated
morbidity. An alternative option is transcatheter device
closure of the foramen ovale (19–26). Preliminary reports
using the Bard Clamshell Septal Occluder Device (Bard
Clamshell Septal Umbrella, USCI Division, C. R. Bard,
Billerica, Massachusetts) and the Buttoned Device (Pediat-
ric Cardiology and Custom Medical Devices, Amarillo,
Texas) to close PFOs for presumed paradoxical emboli have
been encouraging (19,20,24,25). Recently, the Cardio-
SEAL Septal Occluder Device (NMT Medical Inc, Boston,
Massachusetts), a second-generation version of the Bard
Clamshell Septal Occluder Device, has become available for
transcatheter device closure.
We have previously reported our initial experience with
transcatheter closure of PFO using the Bard Clamshell
Septal Occluder Device in patients believed to be at high
risk for recurrent neurological events due to paradoxical
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emboli (19). This study extends the follow-up for this
cohort of patients with additional patients included who had
undergone placement of either the CardioSEAL Septal
Occluder Device or Buttoned Device for presumed para-
doxical emboli.
METHODS
Patient population. Patients were included who under-
went transcatheter closure of a PFO at Children’s Hospital
in Boston, Massachusetts or Massachusetts General Hos-
pital, Boston, following one or more presumed paradoxical
systemic events. All patients had had prior evaluations
regarding the etiology of systemic embolic events, including
transient ischemic attacks (TIA), cerebrovascular accidents
(CVA), peripheral embolic events or brain abscesses in the
absence of any other identifiable cause of systemic emboli,
and were believed to have had presumed paradoxical emboli.
The characteristics and prior evaluations of patients who
had undergone placement of the Bard Clamshell Septal
Occluder Device have been previously reported (19). Eval-
uation of individual patients varied but included magnetic
resonance imaging (MRI), computed tomographic (CT)
examinations, cerebral angiography, carotid ultrasounds,
Holter monitoring, echocardiography and lower extremity
noninvasive evaluation. All patients had evidence of a PFO
by transthoracic or transesophageal echocardiography. A
PFO was defined as a valve-like opening between septum
primum and septum secundum without evidence of an
anatomic defect in the septa. Patients with another known
etiology for an embolic event, or other structural heart
disease, including secundum atrial septal defects, were
excluded.
All patients were enrolled in investigational protocols
approved by the Food and Drug Administration as well as
by the internal review board for each respective hospital or
underwent device placement emergently on a case-by-case
basis. Informed consent was obtained in all patients. Pa-
tients enrolled at Children’s Hospital underwent transcath-
eter closure with the Bard Clamshell Septal Occluder
Device (Clamshell) between March 1989 and October
1994, and with the CardioSEAL Septal Occluder Device
(CardioSEAL) between September 1996 and November
1997. Patients enrolled at Massachusetts General Hospital
underwent transcatheter closure with the Buttoned Device
between January 1995 and November 1997.
Device implantation. The design and technique of trans-
catheter device implantation across the interatrial septum
for the Clamshell and Buttoned Devices have been de-
scribed previously (19–22). The technique of implantation
of the CardioSEAL Device is similar to that of the
Clamshell Device. In order to provide a generally well
tolerated form of antithrombotic therapy for a period of
time until the device becomes fully endothelialized, which
in experimental animal models can occur between four and
12 weeks, daily aspirin therapy was recommended for a
period of six months following device placement. A per-
centage of patients who were receiving anticoagulant ther-
apy with warfarin prior to device placement, continued on
warfarin therapy following device placement because of
other medical conditions such as hypercoagulable state,
multiple deep vein thrombosis (DVT) episodes or malig-
nancy.
Data collection. Data were collected from research and
hospital records, as well as through communication with
referring physicians. The investigational protocols specified
evaluation, including a history, physical examination, chest
X-ray, electrocardiogram and transthoracic echocardiogra-
phy, at one, six and 12 months following device implanta-
tion, and subsequently at yearly intervals with data obtained
per protocol when possible. Follow-up data were obtained
from March 1989 to May 1998. Device position and
stability were determined by transthoracic or transesopha-
geal two-dimensional echocardiography. Among the differ-
ent protocols, the presence and grade of any residual atrial
level shunt were determined by transthoracic or transesoph-
ageal echocardiography using Doppler color mapping or
agitated saline solution contrast injection. The grading of
residual leaks for the Clamshell, CardioSEAL and But-
toned Devices were similar and categorized as none to trivial
(no detectable leak or ,1 mm in the diameter of the color
jet), mild (1 to 3 mm in diameter color jet) and moderate
(.3 mm in diameter color jet).
Statistical analysis. An actuarial risk of recurrent embolic
events at the time of the latest event was determined using
the Kaplan-Meier life table analysis method. The annual
risk of recurrence was calculated from the actuarial risk
using the following formula:
Rannual 5 1 2 @1 2 Ractuarial#1/years.
Statistical analysis was performed using software (SAS 6.12;
SAS Institute; Cary, North Carolina).
RESULTS
Patient characteristics. A total of 63 patients were en-
rolled in the study: 28 in the Clamshell group, 13 in the
CardioSEAL group and 22 in the Buttoned Device group
(Table 1). The mean age was 46 years (range, 20 to 79 years)
and the male-to-female ratio was 1.3:1. The reason for
referral was CVA in 55 patients, TIA in 5 patients, brain
Abbreviations and Acronyms
CT 5 computed tomography
CVA 5 cerebrovascular accident
DVT 5 deep vein thrombosis
MRI 5 magnetic resonance imaging
PFO 5 patent foramen ovale
TIA 5 transient ischemic attack
1312 Hung et al. JACC Vol. 35, No. 5, 2000
Closure of Patent Foramen Ovale for Paradoxical Embolism April 2000:1311–6
abscess in 2 patients and peripheral systemic embolism in 1
patient (axillary artery). Multiple embolic events had oc-
curred in 27 (43%) patients prior to transcatheter device
closure, 12 of whom were being treated with warfarin
anticoagulation at the time of the recurrent event. Fifty-four
percent of patients had at least one of the following risk
factors: hypertension (9%), coronary artery disease (3%),
tobacco use (14%), hypercoagulable state (11%), history of
DVT or pulmonary embolism (11%) and/or oral contracep-
tive use (6%).
Device placement and residual shunt. In the Clamshell
and CardioSEAL Device groups, all patients had successful
deployment of the device. In the Buttoned Device group,
two patients required deployment of a second counter-
occluder due to suboptimal positioning of the first counter-
occluder. Effective closure (trivial or no residual shunt) was
accomplished in 54 of 63 (86%) patients at the time of
device placement or subsequently. Mild shunts remained in
7 (11%) patients and moderate shunts remained in 2 (3%)
(Table 2).
Follow-up. The mean follow-up was 2.6 6 2.4 years (0.1
to 8.2 years) for a total of 164 patient-years (Table 3). There
were four deaths during the follow-up period, none of
which was believed to be related to the device: one death
was from sepsis following a hip fracture in a patient with
end-stage renal failure, a second was from a pulmonary
embolism in a patient who had a hypercoagulable state and
prior to device placement had had multiple pulmonary
embolisms and CVAs, a third death was from lung cancer
and a fourth death was from leukemia.
At the time of the procedure, 39 (62%) patients were
using anticoagulation therapy whereas at the time of follow-
up, 11 (17%) of the patients were using anticoagulation
therapy with 29 (46%) receiving aspirin (Table 3).
No patients had documented atrial fibrillation or flutter
prior to implantation of the device. Four patients were
noted to have atrial fibrillation during or subsequent to
device placement; two had transient atrial fibrillation during
device implantation and two had paroxysmal atrial fibrilla-
tion noted during the follow-up period. Of the latter two,
one occurred at two weeks and the second at three months
following device closure. Both of these patients at the time
of last follow-up were noted to be in sinus rhythm.
Recurrent neurological events. There were four recurrent
neurological events: one stroke and three transient events.
The recurrent stroke occurred in a 56-year-old woman who
had suffered two CVAs before device placement and had
undergone an extensive neurological evaluation, including
magnetic resonance angiography and carotid ultrasonogra-
phy that showed no stenoses, normal results from a Holter
monitor and normal protein C, S and antithrombin III
levels. An echocardiogram had demonstrated a hypermobile
interatrial septum with a PFO and evidence of significant
right-to-left shunt flow on agitated saline solution contrast
injection. Because the etiology of her multiple CVAs was
believed to be due to paradoxical emboli, she underwent
closure of her foramen with a CardioSEAL Device. New
neurological symptoms subsequently developed in this pa-
tient six months following device placement, and another
brain MRI scan showed evidence of a new stroke. A
transesophageal echocardiogram showed a well seated de-
vice without evidence of residual shunting by color Doppler
or agitated saline solution contrast injection. The interatrial
septum was no longer hypermobile.
There were three transient neurological events without
evidence of permanent neurological residua. One occurred
in a 31-year-old woman with a history of a stroke, who had
right-sided visual disturbances three months following
placement of a Clamshell Device. A CT scan of the head
showed no evidence of a new stroke, and a transesophageal
echocardiogram revealed a well seated device with evidence
of a mild residual shunt. Because of a persistent residual
shunt, she was offered another attempt at complete closure
with another device or surgical closure. She elected to
undergo surgical closure. At the time of surgery, the surgeon
decided not to remove the device, as it had become fully
endothelialized, and sutured closed a small residual defect.
A second event occurred in a 44-year-old man who
Table 1. Patient Characteristics
Device n Age (yr) CVA TIA
Brain
Abscess
Other
Systemic
Events
Multiple
Events
Warfarin
Prior to
Device
Clamshell 28 44 6 15 22 3 2 1 15 15
CardioSEAL 13 43 6 13 12 1 0 0 8 10
Buttoned 22 49 6 23 21 1 0 0 4 14
Total 63 46 6 18 55 5 2 1 27 39
CVA 5 cerebrovascular accident; TIA 5 transient ischemic attack.
Table 2. Residual Shunt
Device n
None or
Trivial Mild Moderate
Clamshell 28 24 4 0
CardioSEAL 13 11 1 1
Buttoned 22 19 2 1
Total 63 54 (86%) 7 (11%) 2 (3%)
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developed a transient episode of blurred vision and slurred
speech three years following placement of a Clamshell
Device. A CT scan of his head showed no evidence of a
cerebral infarction. Echocardiography demonstrated a left
atrial mass that appeared to be associated with a fractured
left atrial device arm that was approximating the posterior
wall of the left atrium (“friction lesion”). The device was
well seated and there was no evidence of residual shunt flow.
This patient underwent surgical removal of the device and
mass and closure of his foramen without complications.
The third event occurred in a 19-year-old male patient
who had a brain tumor and who had multiple transient
neurological symptoms that his neurologists believed were
atypical for this patient’s brain lesion. Evaluation had
demonstrated a PFO that was closed with a Clamshell
Device prior to the patient initiating chemotherapy. Fol-
lowing device closure, this patient continued to have similar
neurological symptoms.
Risk of recurrent neurological event. A Kaplan-Meier
lifetable analysis for the 63 patients in this study revealed an
actuarial risk of recurrent neurological events of 9.5% at 3.1
years (95% confidence interval, 0%, 20.3%) resulting in a
calculated annualized risk of 3.2% (Fig. 1). Stratification of
this analysis by potential predictors of recurrent events
following device closure, including age, gender, presence of
residual shunt, warfarin anticoagulation following device,
device type and multiple neurological events prior to device,
revealed no significant differences (Table 4).
Complications. Device arm fractures have been described
previously for both the Clamshell and CardioSEAL Devices
(19,27–30). Ten of 28 patients in the Clamshell Device
group were noted to have fractures, one of which, as
previously stated, was associated with a friction lesion from
rubbing of the fractured device against the left atrial wall.
There have been no significant complications associated
with the remaining nine patients with fractures. In the
CardioSEAL Device group, 5 of 13 patients were noted to
have incidental device arm fractures at routine follow-up
visits. There have been no complications associated with
these device arm fractures, and none of these patients have
had surgical removal of their devices.
Two of 22 patients in the Buttoned Device group
underwent surgical closure of PFO because of malalignment
of the device with significant residual shunting. Both
Figure 1. Kaplan-Meier analysis of the recurrence rate of stroke or
transient ischemic attack following transcatheter device closure.
Table 3. Follow-up Data
Device n
Follow-up
(yr) Deaths
Recurrent
Neurological
Events
Surgical
Repair
Warfarin Therapy
After Device
ASA
Therapy
After Device
Clamshell 28 4.7 6 2.2 2 3 2 4 11
CardioSEAL 13 0.6 6 0.3 1 1 0 3 9
Buttoned 22 1.3 6 1.0 1 0 2 4 9
Total 63 2.6 6 2.4 4 (6%) 4 (6%) 4 (6%) 11 (17%) 29 (46%)
ASA 5 aspirin.
Table 4. Stratified Kaplan-Meier Lifetable Analyses
Annualized
Event Rate (%)
p
Value
Age (yr)
#45 6.4 NS
.45 7.9
Gender
Male 3.6 NS
Female 18.1
Residual shunt
Trivial or none 3.3 NS
Mild or
moderate
37.6
Warfarin
Yes 0.0 NS
No 4.1
Device type
Clamshell 4.0 NS
CardioSEAL 19.1
Buttoned 0.0
Multiple prior
events
Yes 9.5 NS
No 12.6
NS 5 not significant.
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patients had successful initial device placement and were
noted on the six-month follow-up echocardiography to have
partial malalignment of the devices with significant residual
shunting. Both underwent successful surgical removal of the
devices and closure of their PFOs.
DISCUSSION
The present study reports the intermediate follow-up of
patients following transcatheter closure of PFO for pre-
sumed paradoxical emboli at two institutions with particular
reference to the incidence of recurrent embolic neurological
events. Among 63 patients followed up for a mean of 2.6
years (164 patient-years), there were four recurrent neuro-
logical events: one stroke and three transient events. Actu-
arial analysis of these data revealed an annualized risk of
3.2% for recurrent stroke or TIA following transcatheter
closure of the foramen.
Estimation of recurrence risk in patients with stroke and
PFO. A number of studies have estimated the recurrence
risk of stroke or TIA following an initial stroke in patients
with PFO (1,31–34). In one of the larger series examining
this, Bogousslavsky et al. (1) followed up 140 patients (mean
age, 44 years) with an initial stroke or TIA and a PFO,
noting a risk of recurrent stroke or TIA of 3.8% per year
(14); however, depending on the presence of certain risk
factors, they predicted recurrence rates to be .50% in high
risk groups. In another study by Mas et al. (34), in which
132 patients with cryptogenic stroke and PFO (mean age,
40 years) were examined for recurrent stroke or TIA
following an initial neurological event, the calculated recur-
rence risk ranged from 3.4% to 11% per year.
Although the above-mentioned studies provide insights
into the risk of recurrent stroke or TIA in patients with
stroke and a PFO, direct comparison of prior studies to this
present study should be made with caution, as the patient
populations differ in important ways. Most notably, 43% of
patients in the present study had had multiple neurological
events prior to entry into the study, suggesting that they
may have been at higher risk for a recurrent event compared
with the patients in previously published studies, all of
whom had had only one neurological event at the time of
entry.
The wide range of recurrence rates noted in prior studies
underscores the difficulties in identifying patients at greatest
risk of recurrent neurological embolic events attributable to
a PFO. Although paradoxical embolism has been recog-
nized increasingly as a cause of embolic stroke, it is often a
diagnosis of exclusion, as direct demonstration of the
passage of emboli through the foramen is rare (1,7,19,35).
Consequently, there are inevitably patients in whom pre-
sumed embolic events are erroneously attributed to para-
doxical emboli. For example, in the present study, one
patient had a recurrent stroke following device placement
despite a normally positioned device and without evidence
of a residual shunt by color Doppler or agitated saline
solution contrast injection during transesophageal echocar-
diography, suggesting that the etiology of her multiple prior
strokes was, in fact, not due to paradoxical emboli. A similar
experience was reported by Homma et al. (8) who noted
four recurrent neurological events among 28 patients despite
successful surgical closure of the PFO. The success of any
technique designed to prevent recurrent paradoxical embolic
phenomena will depend highly on the success with which
patients at high risk for true paradoxical emboli can be
identified.
In addition, the success of device closure in particular will
also depend on closure of the PFO with full endotheliali-
zation. In two of our patients, technical factors with
suboptimal device performance may have contributed to
recurrent events. As the experience with these devices
increases, however, there are likely to be modifications that
may reduce the incidence of such problems.
Study limitations. Because of the small number of recur-
rent events, this study was underpowered to detect clinically
important differences when stratifying by age, gender, re-
sidual shunt, anticoagulation during follow-up, device type
and history of multiple neurological events prior to device
closure. In addition, this study was without a true control
group, lacking even a comparable historical comparison,
preventing one from drawing a clear conclusion regarding
the impact of transcatheter closure on the risk of recurrent
neurological events. Such a relationship would be best
demonstrated through a randomized clinical trial. Never-
theless, transcatheter closure of the PFO appears to be a
promising option, especially in patients who are unable to
tolerate long-term anticoagulation or who are poor surgical
candidates in the treatment of paradoxical embolism.
CONCLUSIONS
Transcatheter closure of PFO is an alternative therapy in
the prevention of presumed paradoxical emboli in selected
patients. Improved device performance may reduce the risk
of recurrent neurological events. Further studies are neces-
sary to identify the patients most likely to benefit from this
intervention, particularly relative to alternative therapies
such as surgical closure of the PFO or long-term anticoag-
ulation.
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